

Filed: February 8, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

APOTEX INC., APOTEX CORP., APOTEX PHARMACEUTICALS  
HOLDINGS INC., AND APOTEX HOLDINGS, INC.,

Petitioner,

v.

OSI PHARMACEUTICALS, INC.,

Patent Owner.

---

Case IPR2016-01284  
Patent No. 6,900,221 B1

---

**PATENT OWNER'S UPDATED EXHIBIT LIST**

## PATENT OWNER'S UPDATED EXHIBIT LIST

Exhibit No.	Description
2001	J. Cosaert & E. Quoix, <i>Platinum drugs in the treatment of non-small cell lung cancer</i> , 87 British J. Cancer 825 (2002)
2002	Hirotsugu Kenmotsu & Yusuke Tanigawara, Pharmacokinetics, dynamics and toxicity of docetaxel: <i>Why the Japanese dose differs from the Western dose</i> , 106 Cancer Sci. 497 (2015)
2003	Elise A. Sudbeck et al., <i>Tyrosine Kinase Inhibitors Against EGF Receptor-Positive Malignancies</i> , 166 Methods in Molecular Biology 193 (2001)
2004	Center for Drug Evaluation and Research Approval Package for: Application Number 21-743 for Tarceva™
2005	Package Insert for Tarceva® (revised September 2016)
2006	J.R. Woodburn et al., <i>ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development</i> , 38 Proceedings Am. Assoc. for Cancer Research 633 (1997)
2007	Cover Page and Table of Contents for Volume 105 of the Journal of Clinical Investigation (2000)
2008	Ramaswamy Govindan, <i>Phase III failure rates in oncology drugs unacceptable</i> , 16 Oncology News International 1 (2007)
2009	O.S. Breathnach et al., <i>Twenty-Two Years of Phase III Trials for Patients with Advanced Non-Small Cell Lung Cancer: Sobering Results</i> , 19 J. Clinical Oncology 1734 (2001)
2010	OSI Pharmaceuticals, Inc. 2004 Annual Report
2011	Novelos Therapeutics Discontinues Current Development Program for NOV-002 in NSCLC – Business Wire

Exhibit No.	Description
2012	Novartis AG Stops Lung Cancer Drug Trial of ASA404 Developed in Partnership with Antisoma PLC Books \$120 Million Charge
2013	OSI Pharmaceuticals, Inc. 2005 Annual Report
2014	OSI Pharmaceuticals, Inc. 2008 Annual Report
2015	Declaration of Amy K. Wigmore in Support of Motion for Admission <i>Pro Hac Vice</i>
2016	Stipulated Order Narrowing the Issues in the Litigation and IPR Proceeding, C.A. No. 15-772, Dkt. No. 74 (D. Del. Jan. 25, 2017).

**CERTIFICATE OF SERVICE**

Pursuant to 37 C.F.R. § 42.6(e), I certify that I caused to be served a true and correct copy of the foregoing **Patent Owner's Updated Exhibit List** together with **Exhibit 2016**, by electronic mail on:

Aaron S. Lukas  
W. Blake Coblentz  
Cozen O'Connor  
1200 19th Street, N.W.  
Washington, D.C. 20036  
Telephone No.: 202-912-4800  
[wcoblentz@cozen.com](mailto:wcoblentz@cozen.com)  
[alukas@cozen.com](mailto:alukas@cozen.com)

\_\_\_\_/Jonathan Ben-Ur Roses/\_\_\_\_  
Jonathan B. Roses  
Reg. No. 61,115  
Wilmer Cutler Pickering Hale and  
Dorr LLP  
60 State Street  
Boston, MA 02109  
[jonathan.roses@wilmerhale.com](mailto:jonathan.roses@wilmerhale.com)  
617-526-6048